Experts within our Life Science Hub supported Abbott Laboratories to quantify the impact of reducing initial amputations in Peripheral Arterial Disease (PAD) and Chronic Limb-Threatening Ischemia (CLTI) patients. This economic modelling was designed to demonstrate the potential impacts on NHS resource use and budgets across England and Wales.
Our business intelligence and analytics specialists developed an interactive model utilising data from the Kent Integrated Dataset and the National Vascular Registry. This model enabled instant, customisable cost analyses for individual centres, Integrated Care Systems (ICSs), or nationwide assessments.
The reduced-amputation pathway successfully demonstrated the potential net cost savings. The findings were robust under sensitivity tests, ensuring reliability and validity. The client praised the model’s clarity and the balance of the technical report, highlighting its effectiveness in addressing the challenge.
Read more about our Life Science Hub.